MOTS-c Evidence Guide
Evidence for MOTS-c is too preliminary to support a research protocol with confidence. All published data comes from preclinical models and a single small human study that has not been independently replicated. The mitochondrial peptide concept is scientifically novel, but there is no established human dosing, pharmacokinetics, or safety profile. Of the Anti-Aging & Longevity compounds in this library, NAD+ precursors (NMN/NR) have substantially more human data as a starting point.
Our Take
Evidence for MOTS-c is too preliminary to support a research protocol with confidence. All published data comes from preclinical models and a single small human study that has not been independently replicated. The mitochondrial peptide concept is scientifically novel, but there is no established human dosing, pharmacokinetics, or safety profile. Of the Anti-Aging & Longevity compounds in this library, NAD+ precursors (NMN/NR) have substantially more human data as a starting point.
- Evidence context
- Mitochondrial biology research, insulin sensitization mechanistic studies (preclinical only)
- Evidence grade
- Level D
- Confidence
- Low
- Reference context
- Reported research reference: No established human protocol - animal doses of 5mg/kg provide no reliable human translation
Benefits and Evidence
- Metabolic Homeostasis: Level D, mostly non-human evidence - Prevents diet-induced obesity and insulin resistance in mouse models through AMPK activation and enhanced glucose metabolism in skeletal muscle.
- Exercise Performance: Level D, mostly non-human evidence - Improved physical performance and endurance in aged mice, with effects comparable to regular exercise training. Circulating levels increase with exercise in humans.
- Cellular Stress Resistance: Level D, mostly non-human evidence - Enhances cellular stress resistance and promotes survival under metabolic stress conditions through nuclear translocation and ARE-mediated gene expression.
- Host Defense Signaling: Level D, mostly non-human evidence - A 2026 eLife study identified direct antibacterial and interferon-linked immunomodulatory activity, including protection in a mouse MRSA peritonitis model. This expands the proposed biology but remains preclinical and does not establish an anti-infective treatment.
Side Effects and Warnings
- No adequate human exposure or safety dataset has been identified
- Potential immunogenicity and peptide-related impurity risks are unresolved
- No significant adverse effects were reported in the cited animal studies at tested doses
- Extremely limited human data - preclinical research only
- No established human dosing or safety profile
- Quality and purity of commercially available peptide cannot be guaranteed
- Long-term effects of exogenous administration unknown
Research Dosage References
- <strong>Intraperitoneal injection (animal studies)</strong> - 5-15 mg/kg - Daily or 3 times weekly - Dosages from animal research only. No established human dosing. Human clinical trials have not been completed.
Mechanism of Action
MOTS-c acts as a mitochondrial-derived signaling peptide that translocates to the cell nucleus during metabolic stress, where it regulates nuclear gene expression through interaction with the antioxidant response element (ARE) and other stress-responsive promoter elements. This represents a novel form of mitochondria-to-nucleus retrograde signaling. The primary metabolic effects of MOTS-c are mediated through activation of AMP-activated protein kinase (AMPK), the master cellular energy sensor. AMPK activation by MOTS-c promotes glucose uptake in skeletal muscle, enhances fatty acid oxidation, and inhibits de novo lipogenesis - effects that mirror those of physical exercise. MOTS-c also inhibits the folate cycle and de novo purine biosynthesis, leading to accumulation of the intermediate AICAR (5-aminoimidazole-4-carboxamide ribonucleotide), which is itself a potent AMPK activator. This creates a feedforward loop that amplifies the metabolic effects. Circulating levels of MOTS-c decline with age and are correlated with metabolic dysfunction, suggesting it may play a role in age-related metabolic decline. Exogenous administration in aged mice has been shown to improve physical performance and metabolic parameters.
Legal Status
Not FDA-approved. FDA lists compounded MOTS-c among substances that may present significant safety risks because of potential immunogenicity, peptide-related impurities, and the absence of identified human exposure data. FDA advisory-committee discussion in July 2026 was not approval or a final compounding determination.
Primary Sources
- MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications, 2021.
- The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism, 2015.
- MOTS-c is a mitochondrial-encoded interferon-linked host defense peptide. eLife, 2026.
Quick Answers
Where is the strongest evidence for MOTS-c?
Evidence for MOTS-c is too preliminary to support a research protocol with confidence. All published data comes from preclinical models and a single small human study that has not been independently replicated. The mitochondrial peptide concept is scientifically novel, but there is no established human dosing, pharmacokinetics, or safety profile. Of the Anti-Aging & Longevity compounds in this library, NAD+ precursors (NMN/NR) have substantially more human data as a starting point. Evidence context: Mitochondrial biology research, insulin sensitization mechanistic studies (preclinical only).
What are the main side effects of MOTS-c?
MOTS-c side effects and warning signals include No adequate human exposure or safety dataset has been identified, Potential immunogenicity and peptide-related impurity risks are unresolved, No significant adverse effects were reported in the cited animal studies at tested doses, Extremely limited human data - preclinical research only, and No established human dosing or safety profile.
What evidence level is MOTS-c?
MOTS-c is rated Level D; the listed research status is Preclinical.